Skip to Content
Merck
  • Analgesic properties of the novel compound M43068 in rat models of acute and neuropathic pain.

Analgesic properties of the novel compound M43068 in rat models of acute and neuropathic pain.

European journal of pharmacology (2005-10-18)
Yasushige Akada, Reiko Mori, Yutaka Kato, Fumiaki Yamasaki, Hidenori Mochizuki
ABSTRACT

We investigated the effects of 2-(4-hydroxybenzoyl)amino-2-methylpropionic acid (M43068), a novel analgesic agent, in rat models of acute and neuropathic pain. Oral M43068 (10-100 mg/kg) suppressed only the late phase of formalin-induced nociceptive behaviors. In the neuropathic pain model, oral M43068 (10-100 mg/kg) suppressed mechanical allodynia in the nerve-injured paw without affecting normal thresholds. On the other hand, i.v. M43068 (30 mg/kg) mainly suppressed the Abeta-fiber-mediated response with the Neurometer. I.c.v. pretreatment with the alpha1-adrenoceptor antagonist, prazosin, or i.p. pretreatment with the gamma-aminobutyric acid (GABA)B receptor antagonist, saclofen, abolished the M43068-induced antinociception. However, oral M43068 (30-300 mg/kg) had no influence on blood pressure and motor function, unlike the alpha1-adrenoceptor and the GABAB receptor agonists. These data indicate that M43068 shows antinociceptive and anti-allodynic effects with reduced risks of side effects. It is suggested that the descending noradrenergic system is involved in the analgesic effects of M43068.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Saclofen, solid
Sigma-Aldrich
R(+)-Baclofen hydrochloride, solid